Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma
Clinical trial NCT04899427 · UNKNOWN
Trial details
- NCT number
- NCT04899427
- Sponsor
- Peking Union Medical College Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-24
- Primary completion
- 2023-03-24
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.